|
市場調査レポート
商品コード
1451011
再生医療市場レポート:タイプ別、用途別、エンドユーザー別、地域別、2024年~2032年Regenerative Medicine Market Report by Type, Application, End User, and Region 2024-2032 |
||||||
カスタマイズ可能
|
再生医療市場レポート:タイプ別、用途別、エンドユーザー別、地域別、2024年~2032年 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2~3営業日
|
再生医療の世界市場規模は、2023年に222億米ドルに達しました。今後、IMARC Groupは、市場が2032年には1,161億米ドルに達し、2024年から2032年にかけて19.6%の成長率(CAGR)を示すと予測しています。移植拒絶反応の懸念の増大、整形外科疾患に対する再生療法への需要の高まり、歯科再生の増加、創傷治癒における医薬品の使用の拡大などが、市場を推進している要因の一部です。
再生医療は、損傷した組織や臓器の修復に焦点を当てた有望な生物医学分野です。再生医療は、骨、軟骨、血管、重要な臓器の再生を促すために、実験室で培養された幹細胞を利用し、安全に体内に移植するものです。この多次元的なアプローチは、免疫調節や組織工学的手法を含む細胞再生療法や無細胞再生療法を包含しています。組織修復にとどまらず、再生医療はアルツハイマー病、パーキンソン病、心血管疾患(CVDs)、骨粗鬆症、脊髄損傷などの慢性疾患の治療において計り知れない可能性を秘めています。研究が進むにつれて、患者の生活やヘルスケアの成果を大幅に改善できる革新的な治療法への期待が高まっています。
世界市場は主に高齢化人口の増加によって牽引されています。これに伴い、糖尿病、心臓病、変形性関節症などの慢性疾患の有病率が上昇しており、市場の成長に大きく寄与しています。さらに、幹細胞治療や遺伝子工学の研究が活発化していることも、再生医療における技術革新を後押ししています。組織の再生や修復のために幹細胞やその他の細胞ベースの治療法の利用が拡大していることも、市場の活性化に拍車をかけています。さらに、再生医療の研究開発に対する資金援助や規制支援が、市場に明るい見通しをもたらしています。さらに、バイオテクノロジーの進歩により、より精密で効果的な再生治療が可能になり、市場を強化しています。さらに、再生治療の選択肢に関する患者の意識の高まりが市場を後押ししています。
がん治療における製品需要の増加
がん治療における製品需要の増加が市場を活性化しています。制御不能な細胞増殖を特徴とするがんは、しばしば組織の損傷につながりますが、これは再生療法によって対処することができます。再生医療は、がんや化学療法のような治療の副作用によって損傷した組織を修復できる標的療法の開発を可能にします。従来のがん治療の衰弱させる副作用を最小限に抑え、患者の全体的な生活の質を高めることを目的としています。これらの技術は腫瘍微小環境の調節に役立ち、がんの進行を抑制する可能性があります。また、治療中に影響を受けた免疫細胞や組織を修復することで、新たながん免疫療法を補完することもできます。活発な調査と臨床試験は、様々ながんの種類における再生療法の可能性を探り、市場の成長を促進しています。再生療法ががん治療に革命をもたらす可能性があることから、研究開発への投資が集まっています。がんの有病率の上昇と、より効果的で患者に優しい治療の追求は、がん治療における再生医療への需要を煽り、市場の拡大に大きく寄与しています。
免疫療法の急速な進歩
免疫療法の急速な進歩が市場を後押ししています。再生医療のサブセットである免疫療法は、がんや自己免疫疾患などの疾患と闘うために身体の免疫システムを利用します。CAR-T細胞療法や免疫チェックポイント阻害剤のような免疫療法は、がん細胞を認識して闘う身体の能力を強化することにより、がん治療に革命をもたらしました。免疫療法の動向は、より個別化された治療アプローチを可能にし、プレシジョン・メディシンのトレンドに合致しています。免疫療法は、化学療法や放射線療法のような従来の治療法よりも重篤な副作用が少なく、患者の予後を改善することが増えています。研究者たちは、治療効果を高めるために免疫療法を再生アプローチと組み合わせることを模索しており、再生医療の範囲を拡大しています。免疫療法を最適化するための臨床試験や調査研究が活発に行われ、この分野の技術革新が推進されています。免疫療法は、自己免疫疾患、感染症、臓器移植など、がん以外への応用も研究されています。免疫療法が疾病管理を一変させる可能性があることから、研究開発には多額の投資が行われています。免疫療法に対する患者の支持と認知度の向上が、免疫療法の採用と市場成長に寄与しています。
美容外科と美容整形における幅広い製品用途
美容整形や美容分野での幅広い製品応用は、この市場セグメントの成長の促進要因となっています。脂肪由来幹細胞治療を含む再生療法は、乳房再建や顔の若返りのような施術における自然な組織増強のために使用されます。血小板を豊富に含む血漿(PRP)療法や幹細胞を用いた治療など、革新的なアンチエイジング治療を提供し、若々しい外見を求める人々にアピールしています。再生技術は、手術や事故、怪我による瘢痕の見た目を最小限に抑え、審美的な結果を高めるために採用されています。幹細胞ベースの再生療法は毛髪再生に利用され、脱毛などの悩みに対処します。低侵襲の美容再生手技の台頭は、回復時間の短縮と傷跡の軽減を求める患者にアピールしています。再生美容の需要は成長し続けており、この分野への投資や技術革新を引き寄せています。再生美容施術における高い患者満足度と良好な結果は、口コミによる紹介と市場の拡大を促進しています。
The global regenerative medicine market size reached US$ 22.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 116.1 Billion by 2032, exhibiting a growth rate (CAGR) of 19.6% during 2024-2032. The increasing transplant rejection concerns, the rising demand for regenerative therapies for orthopedic conditions, the growing dental regeneration, and the escalating medicine use in wound healing are some of the factors propelling the market.
Regenerative medicine represents a promising biomedical science field focused on restoring damaged tissues and organs. It harnesses laboratory-cultivated stem cells, safely transplanted into the body to stimulate the regeneration of bones, cartilage, blood vessels, and vital organs. This multidimensional approach encompasses cellular and acellular regenerative therapies, including immunomodulation and tissue engineering techniques. Beyond tissue repair, regenerative medicine holds immense potential in treating chronic ailments like Alzheimer's, Parkinson's, cardiovascular diseases (CVDs), osteoporosis, and spinal cord injuries. As research advances, it offers hope for transformative treatments that could significantly improve patients' lives and healthcare outcomes.
The global market is majorly driven by the increasing aging population. In line with this, the rising prevalence of chronic diseases such as diabetes, heart disease, and osteoarthritis is significantly contributing to the market growth. Furthermore, the growing research in stem cell therapies and genetic engineering drives innovation in regenerative medicine. The escalating use of stem cells and other cell-based therapies for tissue regeneration and repair is also catalyzing the market. Moreover, the funding and regulatory support for regenerative medicine research and development are creating a positive outlook for the market. Besides, the advancements in biotechnology enable more precise and effective regenerative therapies, bolstering the market. Additionally, the increasing awareness among patients about regenerative treatment options is providing a boost to the market.
Increasing product demand in cancer treatment
The increasing product demand in cancer treatment is catalyzing the market. Cancer, characterized by uncontrolled cell growth, often leads to tissue damage, which can be addressed through regenerative therapies. Regenerative medicine allows for the development of targeted therapies that can repair damaged tissues caused by cancer or side effects of treatments like chemotherapy. It aims to minimize traditional cancer treatment's debilitating side effects, enhancing patients' overall quality of life. These techniques can help modulate the tumor microenvironment, potentially inhibiting cancer progression. It also complements emerging cancer immunotherapies by repairing immune cells or tissues affected during treatment. Robust research and clinical trials explore the potential of regenerative therapies in various cancer types, fostering market growth. The potential for regenerative therapies to revolutionize cancer treatment attracts investment in research and development. The rising prevalence of cancer and the pursuit of more effective, patient-friendly treatments fuel the demand for regenerative medicine in cancer care, contributing significantly to the market's expansion.
Rapid advancements in immunotherapy
Rapid advancements in immunotherapy are propelling the market. Immunotherapy, a subset of regenerative medicine, harnesses the body's immune system to fight diseases, including cancer and autoimmune disorders. Immunotherapies like CAR-T cell therapy and immune checkpoint inhibitors have revolutionized cancer treatment by enhancing the body's ability to recognize and combat cancer cells. Advances in immunotherapy enable more personalized treatment approaches, aligning with the trend toward precision medicine. They often have fewer severe side effects than traditional treatments like chemotherapy and radiation therapy, improving patient outcomes. Researchers explore combining immunotherapies with regenerative approaches to enhance treatment efficacy, expanding the scope of regenerative medicine. Robust clinical trials and research initiatives focus on optimizing immunotherapies, driving innovation in the field. Immunotherapies are being investigated for applications beyond cancer, including autoimmune diseases, infectious diseases, and organ transplantation. The potential of immunotherapy to transform disease management attracts substantial investments in research and development. Increasing patient advocacy and awareness of immunotherapies contribute to their adoption and market growth.
Widespread product applications in cosmetic surgery and aesthetics
The widespread product applications in cosmetic surgery and aesthetics are a driving force behind the growth of this market segment. Regenerative therapies, including adipose-derived stem cell treatments, are used for natural tissue augmentation in procedures like breast reconstruction and facial rejuvenation. They offer innovative anti-aging treatments, such as platelet-rich plasma (PRP) therapy and stem cell-based interventions, appealing to individuals seeking youthful appearances. Regenerative techniques are employed to minimize the appearance of scars resulting from surgeries, accidents, or injuries, enhancing aesthetic outcomes. Stem cell-based regenerative therapies are utilized for hair restoration, addressing hair loss and baldness concerns. The rise of minimally invasive aesthetic regenerative procedures appeals to patients seeking shorter recovery times and reduced scarring. The demand for regenerative aesthetics continues to grow, attracting investments and innovations in the field. High patient satisfaction rates and positive outcomes in regenerative aesthetic procedures drive word-of-mouth referrals and market expansion.
IMARC Group provides an analysis of the key trends in each segment of the global regenerative medicine market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on type, application, and end user.
Stem Cell Therapy
Biomaterial
Tissue Engineering
Others
Stem cell therapy dominates the market
The report has provided a detailed breakup and analysis of the market based on the type. This includes stem cell therapy, biomaterial, tissue engineering, and others. According to the report, stem cell therapy represented the largest segment.
Stem cell therapy harnesses the unique regenerative properties of stem cells to repair and replace damaged or dysfunctional tissues and organs. It offers diverse therapeutic applications, including orthopedics, cardiology, neurology, and oncology. This versatility attracts investment and research, expanding its market presence. Clinical trials and case studies demonstrate the effectiveness of stem cell therapies in treating previously incurable conditions, boosting patient and physician confidence. With the global population aging, there's an increasing prevalence of age-related diseases and degenerative conditions, driving demand for regenerative treatments.
Furthermore, the regulatory bodies recognize stem cell therapies' potential, resulting in streamlined approvals and guidelines, further encouraging market growth. Patients seeking alternatives to conventional treatments are turning to stem cell therapies for better outcomes and reduced side effects. The potential of stem cell therapies attracts investments, fostering research and development and expanding accessibility. Advances in stem cell isolation, culturing, and delivery methods improve treatment efficacy, expanding their applications. Stem cell therapy providers are expanding their reach globally, making these treatments available to a wider patient population.
Bone Graft Substitutes
Osteoarticular Diseases
Dermatology
Cardiovascular
Central Nervous System
Others
Dermatology dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes bone graft substitutes, osteoarticular diseases, dermatology, cardiovascular, central nervous system, and others. According to the report, dermatology represented the largest segment.
Dermatology is a vital application within regenerative medicine, focusing on the restoration and regeneration of skin tissues. It addresses a wide spectrum of dermatological concerns, ranging from scar reduction and wound healing to treating skin disorders and aging-related skin conditions.
Regenerative approaches in dermatology include using stem cells, growth factors, and tissue engineering techniques, offering patients innovative and minimally invasive solutions for achieving healthier, more youthful, and blemish-free skin. This segment is gaining traction due to the growing demand for cosmetic and aesthetic enhancements and the need for effective treatments for various skin ailments, ultimately contributing to the overall growth of the regenerative medicine market.
Hospitals
Specialty Clinics
Others
Hospitals dominate the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, specialty clinics, and others. According to the report, hospitals represented the largest segment.
Hospitals serve as prominent end users within the regenerative medicine market, playing a pivotal role in the adoption and growth of regenerative therapies. They serve as hubs for advanced medical care and are integral for several reasons. Hospitals provide the infrastructure and expertise necessary for conducting complex regenerative procedures, such as organ transplants and stem cell therapies, ensuring patient safety and optimal outcomes. They also facilitate clinical trials and research initiatives, allowing for the development and testing innovative regenerative treatments.
Furthermore, hospitals are key in delivering regenerative therapies to patients, especially acute injuries, chronic diseases, or conditions requiring specialized medical attention. As healthcare institutions embrace regenerative medicine, hospitals remain central in its expansion, offering hope and cutting-edge treatments to a diverse patient population.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America represents a significant region in the regenerative medicine market, driving growth through several key factors. The region's advanced healthcare infrastructure, robust research and development capabilities, and high healthcare expenditure contribute to the adoption of regenerative therapies. It is home to numerous renowned research institutions, biotechnology companies, and academic centers specializing in regenerative medicine, fostering innovation and clinical advancements.
Regulatory support and well-defined approval processes in countries like the United States accelerate the introduction of regenerative treatments to the market. A growing aging population with age-related conditions also fuels the demand for regenerative solutions. Moreover, a strong focus on addressing chronic diseases, sports injuries, and aesthetic concerns further propels the use of regenerative therapies in North America. These factors collectively position North America as a prominent growth driver in the regenerative medicine sector.
Top companies are strengthening the market through innovation, strategic partnerships, and extensive research. They invest heavily in research and development, pushing the boundaries of regenerative medicine, uncovering new therapies, and expanding treatment options. They conduct large-scale clinical trials to demonstrate the safety and efficacy of regenerative therapies, gaining regulatory approvals and boosting market confidence. Top companies develop a diverse portfolio of regenerative products, catering to various medical conditions and applications, from orthopedics to oncology. These companies expand globally, ensuring wider access to their therapies and increasing market reach. Partnerships with research institutions, healthcare providers, and pharmaceutical companies facilitate knowledge sharing and the development of novel therapies. They navigate complex regulatory landscapes, ensuring their therapies meet stringent safety and quality standards instilling trust in healthcare professionals and patients. Top companies engage in patient advocacy and education, raising awareness about the benefits of regenerative medicine, thus driving demand. Their track record of success attracts investments, enabling further research and development of groundbreaking therapies.
The report has provided a comprehensive analysis of the competitive landscape in the regenerative medicine market. Detailed profiles of all major companies have also been provided.
Allergan PLC (AbbVie Inc.)
Amgen Inc.
Baxter International Inc.
BD (Becton, Dickinson and Company)
Integra Lifesciences Holdings Corporation
Medtronic plc
Mimedx Group Inc.
Novartis AG
Osiris Therapeutics Inc. (Smith & Nephew plc)
Thermo Fisher Scientific Inc
In May 2020, AbbVie acquired Allergan, expanding its aesthetics and regenerative medicine portfolio.
In 2021, Amgen initiated clinical trials for regenerative medicine candidates, focusing on stem cell therapies for neurological and cardiovascular conditions.
In 2020, Integra Lifesciences expanded its regenerative product portfolio by launching new wound care solutions.